TYRA
Tyra Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$25.73
+5.32%Sep 14, 2026, 10:45 UTC
Tyra Biosciences priced an underwritten offering of 9,079,000 common shares at $22.03 per share and pre-funded warrants for 9,078,529 shares at $22.029 each, raising about $400 million.
Source:Sep 9, 2026, 16:39 UTC
Tyra Biosciences announced initial results from its Phase 2 SURF302 trial of oral dabogratinib, establishing clinical proof of concept and selecting a 60 mg once-daily dose for planned registrational studies.
Source:Sep 9, 2026, 14:44 UTC
Tyra Biosciences stock plunged 22% after its bladder cancer pill failed to impress in a clinical setting.
Source:Aug 4, 2026, 20:05 UTC
Tyra Biosciences appointed Jonathan Day as EVP, Clinical Development to advance its skeletal dysplasia strategy.
Source:Aug 4, 2026, 20:05 UTC
Tyra Biosciences reported financial results for the second quarter ended June 30, 2026, with cash, cash equivalents and marketable securities of $353.9 million and a runway into the second half of 2028.
Source: